Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

A Phase 1 Trial to Evaluate the Safety, Immunogenicity, and Reactogenicity of Heterologous and Homologous Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04776317

Enrollment

Registered

2021-03-01

Start date

2021-03-25

Completion date

2023-09-15

Last updated

2025-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Immunogenicity, Prime-Boost, Reactogenicity, Safety, SARS-CoV-2, vaccine

Brief summary

This is a multicenter, US-only, phase 1, open-label, dose escalation, non-randomized study of the safety, tolerability, and immunogenicity of investigational ChAd and SAM SARS-CoV-2 vaccines in healthy adult subjects. Homologous and heterologous prime-boost vaccination schedules (Stage 1), as well as boost(s) after receipt of COVID-19 EUA/licensed vaccines (Stage 2) will be examined. Subjects' willingness to receive ChAd vaccines will be assessed and documented at the time of informed consent and considered to determine group assignments. This phase 1 study will enroll 17 Stage 1 and up to 118 Stage 2 subjects. Eligible subjects will be enrolled in different groups based on their age (18-60 years old and \>60 years old) and their EUA/licensed COVID-19 vaccination status. A sentinel approach with 72-hour (Stage 1, and Stage 2, Groups 5, 6, 8-10, 12, 13-15) or 7-day observation times (Groups 7 and 11) will be used, before recruiting the remainder of each dose escalation group. Decisions about dose escalation will be determined by the SSC with consultation with the DSMB as needed after all subjects in each group have been observed through Day 8 post first study vaccination. All subjects will be followed through 12 months after their last study vaccination. Vaccinated subjects will be carefully monitored for exposure and infection to SARS-CoV-2 throughout the study. Escalation to the highest dose (10 µg) of SAM-S-TCE in younger subjects will proceed only following safety assessments of the 10 µg dose in older subjects for a period of 28 days post-vaccination. In addition, the dosage of SAM-S-TCE given as a double boost to subjects previously vaccinated with the Johnson & Johnson/Janssen Ad26 COVID-19 EUA/licensed vaccine in Groups 8A, 8B, and 12A, 12B will be determined based on the dose escalation reactogenicity and immunogenicity results in Groups 5-7 and 9-11, respectively. After protocol version 9.0 was implemented, it was decided not to enroll subjects into Groups 7 and 8 because of competing priorities and predicted difficulties enrolling into these two groups. The primary objectives of this study are 1) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as prime-boost in healthy naïve adult subjects, 2) To assess the safety and tolerability of different doses of ChAd-S or ChAd-S-TCE, and SAM-S or SAM-S-TCE when administered as first or second boost in healthy adult subjects previously vaccinated with an mRNA or adenoviral-vectored COVID-19 EUA/licensed vaccine.

Detailed description

Interventions

BIOLOGICALChAdV68-S

Chimpanzee Adenovirus serotype 68 - Spike (ChAdV68-S) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5 mL intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.

BIOLOGICALChAdV68-S-TCE

Chimpanzee Adenovirus 68 - Spike plus additional SARS-CoV-2 T cell epitopes (ChAdV68-S-TCE) is a replication-defective, E1, E3 E4Orf2-4 deleted adenoviral vector based on chimpanzee adenovirus 68 (C68, 68/SAdV-25, originally designated as Pan 9), which belongs to the sub-group E adenovirus family. A single 0.5- or 1.0-mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.

BIOLOGICALSAM-LNP-S

Self-Amplifying mRNA - Lipid Nanoparticles - Spike (SAM-LNP-S) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 mL or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.

BIOLOGICALSAM-LNP-S-TCE

Self-Amplifying mRNA - Lipid Nanoparticles -Spike plus additional SARS-CoV-2 T cell epitopes (SAM-S-TCE) is a SAM vector based on Venezuelan Equine Encephalitis Virus (VEEV). A single 0.25 or 0.5 mL (depending on dose level) intramuscular injection will be administered in the deltoid muscle. When possible, the prime vaccine and boost vaccine should be administered in different arms.

OTHERSodium Chloride, 0.9%

The diluent used for this study will be 0.9% Sodium Chloride Injection, USP, and is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each milliliter (mL) contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Yes

Inclusion criteria

Subjects eligible to participate in this trial must meet all of the following inclusion criteria: 1. Provide written informed consent prior to initiation of any study procedures 2. Able and willing (in the investigator's opinion) to comply with all study requirements 3. Are men or non-pregnant women aged 18 years or older at enrollment 4. Are in good health\* \*As defined by absence of clinically significant medical conditions defined by the CDC as increasing risk for severe corona virus disease-19 (COVID-19) (see

Exclusion criteria

), or other acute or chronic medical conditions determined by medical history, physical examination (PE), screening laboratory test results, and/or clinical assessment of the investigator that are either listed as

Design outcomes

Primary

Measure	Time frame	Description
Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	Day 1 to study completion through up to 1 year post last dose	Number of participants that experienced any NOCMCs during the course of the study
Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	Day 1 to study completion through up to 1 year post last dose	Number of participants that experienced any PIMMCs during the course of the study
Frequency of Any Medically Attended Adverse Events (MAAEs)	Day 1 to study completion through up to 1 year post last dose	Number of participants that experienced any MAAEs during the course of the study
Frequency of Any Laboratory AE	Through 7 days post each study vaccination	Number of participants that experienced any laboratory AE
Frequency of Any Serious Adverse Events (SAEs)	Day 1 to study completion through up to 1 year post last dose	The number of participants that experience any SAEs from Day 1 to study completion. An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.	Number of participants who experienced any systemic solicited AEs through 7 days post any vaccination. Systemic events include: fatigue, headache, myalgia, arthralgia, nausea, chills and fever.
Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.	Number of participants who experienced any local solicited AEs through 7 days post any vaccination. Local events include: pain at injection site, erythema, and induration.
Frequency of Any Unsolicited Adverse Events (AEs)	Day 1 through Day 29 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and 28 days post any vaccination for Groups 1, 3A, 3b and 4.	Number of participants who experienced any unsolicited AEs through 28 days post vaccination

Secondary

Measure	Time frame	Description
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1
Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5
Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G
Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean of RBD titer
Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Geometric Mean of RBD titer
Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean of RBD titer
Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean of S-2P titer
Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Geometric Mean of S-2P titer
Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean of S-2P titer
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1 S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5 S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against D614G S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P
Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2
Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154 To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination, Day 15 Post Vaccination	Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the S1 as measured by ELISpot
Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the S2 as measured by ELISpot
Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the Spike as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot
Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the S1 as measured by ELISpot
Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the S2 as measured by ELISpot
Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the Spike as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1	Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot.
Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot.
Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot.
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot.
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot.
Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot.
Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot.
Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the S1 as measured by ELISpot.
Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the S2 as measured by ELISpot.
Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the Spike as measured by ELISpot.
Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1	Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot.
Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 29 Post Vaccination 1, Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Day 29 Post Vaccination 1	Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay
Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 169 Post Vac 1 (85 Days Post Vac 2), Day 265 Post Vac 1 (181 Days Post Vac 2), Day 450 Post Vac 1 (366 Days Post Vac 2)	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.
Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from 4 distinct US-based Infectious Diseases Clinical Research Consortium (IDCRC) sites. The first participant was enrolled on March 25, 2021, and the last participant was enrolled on September 29, 2022.

Pre-assignment details

Stage 1 studied dose escalation of homologous and heterologous prime-boost vaccination schedules in healthy naïve adult participants. Stage 2 studied booster vaccination(s) in adult participant who previously received Coronavirus Disease 2019 (COVID-19) Emergency Use Authorization (EUA)/licensed vaccines.

Participants by arm

Arm	Count
Stage 1 (Naïve) Group 1 Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 5 x 10\^10 vp ChAd-S followed by 30 µg SAM-S.	4
Stage 1 (Naïve) Group 3A Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 30 µg SAM-S.	3
Stage 1 (Naïve) Group 3B Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 30 µg SAM-S followed by 3 µg SAM-S.	7
Stage 1 (Naïve) Group 4 Covid-19 Vaccine and infection Naïve, 18-60years old; received intramuscular (IM) injection of 10 µg SAM-S-TCE followed by 3 µg SAM-S-TCE.	3
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5 Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.	10
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6 Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, 18-60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.	10
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9 Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 3 µg SAM-S-TCE.	8
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 6 µg SAM-S-TCE.	10
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 10 µg SAM-S-TCE.	10
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13 Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10\^10 vp ChAd-S-TCE.	7
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14 Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 1x10\^11 vp ChAd-S-TCE.	7
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15 Previously (\>/=112 days) dosed with Emergency Use Authorization (EUA)/licensed mRNA vaccine, greater than 60 years old, received a single intramuscular (IM) injection of 5x10\^11 vp ChAd-S-TCE.	2
Total	81

Withdrawals & dropouts

Period	Reason	FG001	FG002	FG004
Overall Study	Physician Decision	1	0	0
Overall Study	Protocol Violation	0	1	0
Overall Study	Withdrawal by Subject	0	0	1

Baseline characteristics

Characteristic	Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Stage 1 (Naïve) Group 1	Stage 1 (Naïve) Group 3A	Stage 1 (Naïve) Group 3B	Stage 1 (Naïve) Group 4	Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Total
Age, Continuous	32.9 years STANDARD_DEVIATION 12.6	32.5 years STANDARD_DEVIATION 8.9	23.3 years STANDARD_DEVIATION 8.4	45.4 years STANDARD_DEVIATION 11.7	29.3 years STANDARD_DEVIATION 13.6	34.0 years STANDARD_DEVIATION 8.7	63.4 years STANDARD_DEVIATION 2.8	67.8 years STANDARD_DEVIATION 4.7	66.0 years STANDARD_DEVIATION 4.5	69.1 years STANDARD_DEVIATION 7.1	64.7 years STANDARD_DEVIATION 5.3	67.5 years STANDARD_DEVIATION 3.5	51.0 years STANDARD_DEVIATION 18.2
BMI	23.46 kg/m^2 STANDARD_DEVIATION 2.94	25.23 kg/m^2 STANDARD_DEVIATION 3.48	21.03 kg/m^2 STANDARD_DEVIATION 3.18	24.51 kg/m^2 STANDARD_DEVIATION 2.11	25.57 kg/m^2 STANDARD_DEVIATION 3.44	24.79 kg/m^2 STANDARD_DEVIATION 3.05	26.03 kg/m^2 STANDARD_DEVIATION 4.46	24.77 kg/m^2 STANDARD_DEVIATION 4.31	29.26 kg/m^2 STANDARD_DEVIATION 2.69	23.33 kg/m^2 STANDARD_DEVIATION 4.35	26.61 kg/m^2 STANDARD_DEVIATION 4.74	26.55 kg/m^2 STANDARD_DEVIATION 2.47	25.00 kg/m^2 STANDARD_DEVIATION 3.8
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	10 Participants	4 Participants	2 Participants	7 Participants	3 Participants	9 Participants	8 Participants	10 Participants	10 Participants	7 Participants	7 Participants	2 Participants	79 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Previous COVID-19 Infection No previous infection	10 Participants	4 Participants	3 Participants	7 Participants	3 Participants	10 Participants	8 Participants	8 Participants	8 Participants	7 Participants	6 Participants	2 Participants	76 Participants
Previous COVID-19 Infection Previous infection	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	2 Participants	0 Participants	1 Participants	0 Participants	5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Asian	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	9 Participants	4 Participants	2 Participants	7 Participants	3 Participants	9 Participants	8 Participants	10 Participants	10 Participants	6 Participants	7 Participants	2 Participants	77 Participants
Sex: Female, Male Female	6 Participants	0 Participants	0 Participants	4 Participants	0 Participants	7 Participants	5 Participants	6 Participants	7 Participants	5 Participants	2 Participants	0 Participants	42 Participants
Sex: Female, Male Male	4 Participants	4 Participants	3 Participants	3 Participants	3 Participants	3 Participants	3 Participants	4 Participants	3 Participants	2 Participants	5 Participants	2 Participants	39 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk
deaths Total, all-cause mortality	0 / 4	0 / 3	0 / 7	0 / 3	0 / 10	0 / 10	0 / 8	0 / 10	0 / 10	0 / 7	0 / 7	0 / 2
other Total, other adverse events	4 / 4	3 / 3	7 / 7	3 / 3	10 / 10	10 / 10	8 / 8	10 / 10	10 / 10	7 / 7	7 / 7	2 / 2
serious Total, serious adverse events	0 / 4	0 / 3	0 / 7	0 / 3	0 / 10	0 / 10	0 / 8	0 / 10	0 / 10	0 / 7	0 / 7	0 / 2

Outcome results

Primary

Frequency of Any Laboratory AE

Number of participants that experienced any laboratory AE

Time frame: Through 7 days post each study vaccination

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Any Laboratory AE	4 Participants
Stage 1 (Naïve) Group 3A	Frequency of Any Laboratory AE	3 Participants
Stage 1 (Naïve) Group 3B	Frequency of Any Laboratory AE	7 Participants
Stage 1 (Naïve) Group 4	Frequency of Any Laboratory AE	3 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Any Laboratory AE	8 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Any Laboratory AE	8 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Any Laboratory AE	7 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Any Laboratory AE	8 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Any Laboratory AE	10 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Any Laboratory AE	6 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Any Laboratory AE	5 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Any Laboratory AE	0 Participants

Primary

Frequency of Any Medically Attended Adverse Events (MAAEs)

Number of participants that experienced any MAAEs during the course of the study

Time frame: Day 1 to study completion through up to 1 year post last dose

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Any Medically Attended Adverse Events (MAAEs)	0 Participants
Stage 1 (Naïve) Group 3A	Frequency of Any Medically Attended Adverse Events (MAAEs)	1 Participants
Stage 1 (Naïve) Group 3B	Frequency of Any Medically Attended Adverse Events (MAAEs)	4 Participants
Stage 1 (Naïve) Group 4	Frequency of Any Medically Attended Adverse Events (MAAEs)	1 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Any Medically Attended Adverse Events (MAAEs)	4 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Any Medically Attended Adverse Events (MAAEs)	4 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Any Medically Attended Adverse Events (MAAEs)	3 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Any Medically Attended Adverse Events (MAAEs)	3 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Any Medically Attended Adverse Events (MAAEs)	5 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Any Medically Attended Adverse Events (MAAEs)	3 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Any Medically Attended Adverse Events (MAAEs)	1 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Any Medically Attended Adverse Events (MAAEs)	0 Participants

Primary

Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)

Number of participants that experienced any NOCMCs during the course of the study

Time frame: Day 1 to study completion through up to 1 year post last dose

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	0 Participants
Stage 1 (Naïve) Group 3A	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	0 Participants
Stage 1 (Naïve) Group 3B	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	2 Participants
Stage 1 (Naïve) Group 4	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	1 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	2 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	1 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	1 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	1 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	1 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)	0 Participants

Primary

Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)

Number of participants that experienced any PIMMCs during the course of the study

Time frame: Day 1 to study completion through up to 1 year post last dose

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 1 (Naïve) Group 3A	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 1 (Naïve) Group 3B	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	1 Participants
Stage 1 (Naïve) Group 4	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	2 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)	0 Participants

Primary

Frequency of Any Serious Adverse Events (SAEs)

The number of participants that experience any SAEs from Day 1 to study completion. An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.

Time frame: Day 1 to study completion through up to 1 year post last dose

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 1 (Naïve) Group 3A	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 1 (Naïve) Group 3B	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 1 (Naïve) Group 4	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Any Serious Adverse Events (SAEs)	0 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Any Serious Adverse Events (SAEs)	0 Participants

Primary

Frequency of Any Unsolicited Adverse Events (AEs)

Number of participants who experienced any unsolicited AEs through 28 days post vaccination

Time frame: Day 1 through Day 29 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and 28 days post any vaccination for Groups 1, 3A, 3b and 4.

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Any Unsolicited Adverse Events (AEs)	1 Participants
Stage 1 (Naïve) Group 3A	Frequency of Any Unsolicited Adverse Events (AEs)	2 Participants
Stage 1 (Naïve) Group 3B	Frequency of Any Unsolicited Adverse Events (AEs)	6 Participants
Stage 1 (Naïve) Group 4	Frequency of Any Unsolicited Adverse Events (AEs)	3 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Any Unsolicited Adverse Events (AEs)	10 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Any Unsolicited Adverse Events (AEs)	8 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Any Unsolicited Adverse Events (AEs)	7 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Any Unsolicited Adverse Events (AEs)	7 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Any Unsolicited Adverse Events (AEs)	8 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Any Unsolicited Adverse Events (AEs)	6 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Any Unsolicited Adverse Events (AEs)	5 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Any Unsolicited Adverse Events (AEs)	2 Participants

Primary

Frequency of Local Solicited Reactogenicity Adverse Events (AEs)

Number of participants who experienced any local solicited AEs through 7 days post any vaccination. Local events include: pain at injection site, erythema, and induration.

Time frame: Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	4 Participants
Stage 1 (Naïve) Group 3A	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	3 Participants
Stage 1 (Naïve) Group 3B	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	7 Participants
Stage 1 (Naïve) Group 4	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	3 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	10 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	8 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	5 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	8 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	9 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	1 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	2 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Local Solicited Reactogenicity Adverse Events (AEs)	1 Participants

Primary

Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)

Number of participants who experienced any systemic solicited AEs through 7 days post any vaccination. Systemic events include: fatigue, headache, myalgia, arthralgia, nausea, chills and fever.

Time frame: Day 1 through Day 8 for Groups 5, 6, 9, 10, 11, 13, 14 and 15 and through 7 days post any vaccination for Groups 1, 3A, 3b and 4.

Population: The Safety Analysis population for the study includes all participants who received one dose of vaccine.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Stage 1 (Naïve) Group 1	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	4 Participants
Stage 1 (Naïve) Group 3A	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	3 Participants
Stage 1 (Naïve) Group 3B	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	7 Participants
Stage 1 (Naïve) Group 4	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	3 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	10 Participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	10 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	8 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	10 Participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 11A,B	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	10 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 13	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	3 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 14	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	5 Participants
Stage 2 (ChAd-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 15	Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)	2 Participants

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.

Time frame: Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	NA fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.

Time frame: Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 29 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 85 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	1.93 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	28.25 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	11.46 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	13.61 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	2.40 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 29 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 57 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	42.65 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 85 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	4.27 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	1.00 fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.

Time frame: Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.81 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	86.85 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	18.53 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	7.76 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	8.63 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	7.14 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	13.39 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	74.37 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	7.32 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.95 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	9.20 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	40.58 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.49 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	56.02 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	20.73 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.54 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	11.83 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.74 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2.43 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	8.76 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	4.32 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.97 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2.88 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	3.35 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	9.95 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	12.26 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	15.55 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2.53 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	2.01 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	44.10 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	11.77 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.80 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	3.77 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	4.70 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.12 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1.46 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	3.12 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.29 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	3.91 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.26 fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.

Time frame: Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	NA fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.

Time frame: Day 169 Post Vac 1 (85 Days Post Vac 2), Day 265 Post Vac 1 (181 Days Post Vac 2), Day 450 Post Vac 1 (366 Days Post Vac 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	NA fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	NA fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.

Time frame: Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.32 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	121.91 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	23.87 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.08 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.45 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	4.89 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	13.56 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	108.81 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.43 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	3.47 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.11 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	17.31 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	3.38 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	12.57 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.64 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	2.95 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	11.53 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.01 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	1.66 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.67 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.58 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	2.46 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	4.30 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	4.43 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	25.41 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	11.24 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	21.78 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	1.82 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.74 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	84.18 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	11.63 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.85 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	3.66 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	10.54 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.56 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	6.70 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	11.12 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.60 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	9.14 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.78 fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.

Time frame: Day 29 Post Vaccination 1, Day 57 Post Vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 29 Post Vaccination 1	11.90 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)	72.48 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	12.27 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	573.77 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	66.61 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 29 Post Vaccination 1	4.06 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	1.57 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)	2.80 fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination 1 titer.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 29 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 57 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 85 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	1.18 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	1.35 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	1.00 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	258.71 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	42.59 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	130.72 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 29 Post Vaccination 1	9.09 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	17.21 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 57 Post Vaccination 1	1.86 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	298.33 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 85 Post Vaccination 1	1.00 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	9.98 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	23.98 fold rise

Secondary

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G. Fold-rise is calculated by dividing post-vaccination titers by the Day 1 Pre-Vaccination titer.

Time frame: Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	3.33 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	30.20 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	14.19 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	4.96 fold rise
Stage 1 (Naïve) Group 1	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.02 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	3.62 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.75 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	15.28 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	3.38 fold rise
Stage 1 (Naïve) Group 3A	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	3.05 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	8.07 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	10.01 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.64 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	18.02 fold rise
Stage 1 (Naïve) Group 3B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	10.84 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	4.06 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	4.83 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.91 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2.78 fold rise
Stage 1 (Naïve) Group 4	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.60 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.79 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	2.03 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	3.27 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	3.27 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.16 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	11.38 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	13.53 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2.90 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	2.15 fold rise
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	21.98 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	9.94 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1.52 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2.86 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	2.54 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.54 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	0.89 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1.88 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.06 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	2.76 fold rise
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	4.55 fold rise

Secondary

Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of RBD titer

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.6975 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.5864 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.1134 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.1962 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.1082 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.9271 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.2725 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	6.1054 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.2709 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.8714 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.3735 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.3086 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.4872 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.5427 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.4103 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.5019 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.8233 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	4.8833 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.5874 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.2627 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.5201 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.2341 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.3951 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.9260 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.4714 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.2454 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.8235 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.1098 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.6756 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.4238 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	4.7917 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.4978 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.6996 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.5399 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	4.3709 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	6.0125 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.7671 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.6336 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	4.7219 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.1222 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.3922 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	4.8502 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.5832 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.1749 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.5803 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	6.2200 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.1950 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.3734 titer

Secondary

Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of S-2P titer

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.1647 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.2906 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.7415 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.0318 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.5115 titer
Stage 1 (Naïve) Group 1	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.7937 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	6.0754 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.6841 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.0462 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.5361 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.0642 titer
Stage 1 (Naïve) Group 3A	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.5887 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	4.7663 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.1947 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.0168 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	4.8845 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	4.8448 titer
Stage 1 (Naïve) Group 3B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	4.5982 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.2681 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.2196 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.2691 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.5926 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.1933 titer
Stage 1 (Naïve) Group 4	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.3569 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.5167 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.5084 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.3687 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.1658 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.8548 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.6533 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.0920 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.4640 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.0731 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.5953 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	4.5890 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.3688 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5.8416 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.6251 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.3462 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.6380 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.1322 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	5.3743 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	6.4489 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	5.5236 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	5.0425 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	5.7356 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	5.1096 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	6.1184 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1

Time frame: Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	12.8238 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	1611.5218 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	7.3983 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	28.7301 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1

Time frame: Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1, Day 450 Post Vaccination 1

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 29 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	6.9420 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	120.5431 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 85 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	84.8521 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 1 Pre-Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	95.1328 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	85.4674 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 1 Pre-Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 29 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 57 Post vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 85 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	6.6902 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	8.1121 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1779.4509 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	17.7942 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	85.6574 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	153.6259 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	329.7767 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	138.0929 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	238.4406 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	33.4039 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	244.4228 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	2484.3099 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	165.3657 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	447.3343 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	665.0024 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	109.1945 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	77.0553 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	246.0892 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	481.6709 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	11.8710 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	711.0995 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	81.1329 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	141.2683 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	196.8757 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	530.9893 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	959.9418 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	294.2032 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	173.5413 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	875.2497 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	87.9255 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	379.9728 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	253.2367 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	123.3706 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	596.9179 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	97.9557 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	757.4496 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	48.7041 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	2147.7815 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1369.4248 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	711.7177 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	116.3880 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	438.3675 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	546.5955 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	209.5990 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1833.8419 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	2467.0800 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	685.0752 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1459.7959 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	468.5976 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	2008.1706 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5

Time frame: Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	16.3926 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	1345.8006 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	23.6552 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	40.2809 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5

Time frame: Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	54.4021 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	25.9869 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	85.2857 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	74.1983 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1688.7466 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	12.5099 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	54.0724 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	80.7230 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	298.6044 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	76.0077 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	116.9255 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	23.8982 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	129.8719 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	2600.2491 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	82.9652 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	324.0669 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	575.9687 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	280.1679 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	154.9099 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	258.4824 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	793.2778 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	45.8250 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	627.1003 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	94.0770 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	94.8682 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	155.9792 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	277.7532 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1084.8950 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	170.1065 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	94.5667 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	976.0525 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	38.4049 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	252.6360 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	165.0762 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	38.3975 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	236.6733 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	36.6182 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	458.4044 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	21.0485 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1771.7935 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	742.6808 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	360.5940 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	63.8694 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	233.6561 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	673.1993 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	118.0503 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1134.9309 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	717.7161 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	832.4483 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1380.7990 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	124.2137 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	571.0459 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G

Time frame: Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 29 Post Vaccination 1	59.4991 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	61.3577 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	362.4094 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	2868.8374 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 1 Pre-Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	333.0359 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 1 Pre-Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 29 Post Vaccination 1	20.2886 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	14.0063 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	7.8418 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 29 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	6.7531 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 85 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 57 Post vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	1293.5494 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	5.8980 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	212.9680 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 1 Pre-Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	653.5897 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 1 Pre-Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 29 Post Vaccination 1	45.4538 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 57 Post vaccination 1	9.2994 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 85 Post Vaccination 1	5.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	119.8892 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	86.0638 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	49.9195 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	1491.6390 titer

Secondary

Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	3531.7642 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	112.8328 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	376.1197 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	566.1029 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1601.5347 titer
Stage 1 (Naïve) Group 1	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	559.7445 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	1468.7289 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	405.4138 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1371.6395 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	6195.9903 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	1237.9613 titer
Stage 1 (Naïve) Group 3A	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	2738.3033 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1853.2904 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	829.7727 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	682.4080 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1114.9642 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1029.1579 titer
Stage 1 (Naïve) Group 3B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	102.8466 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	3188.0320 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	482.9330 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	921.5980 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	1341.1447 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1963.1115 titer
Stage 1 (Naïve) Group 4	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	2333.8724 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1229.7755 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	761.2916 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1936.6356 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	375.5394 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	2175.7877 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	1229.6606 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	425.4411 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	1670.9884 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	315.1407 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	1986.5339 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	146.8761 titer
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	3228.9682 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	4276.7890 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	2813.3790 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	430.2308 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	1230.7704 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1093.8728 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	652.4332 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination	5078.3770 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post Vaccination	8381.4354 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 366 Post Vaccination	1645.4066 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination	3462.6712 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination	1843.1744 titer
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination	11176.4335 titer

Secondary

Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A

Geometric Mean of RBD titer

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 29 Post Vaccination 1	4.0128 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	4.3994 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)	5.2779 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	6.5014 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 1 Pre-Vaccination 1	1.4663 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	5.8002 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 1 Pre-Vaccination 1	1.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 29 Post Vaccination 1	1.3351 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 57 Post Vaccination 1 (29 Days Post Vaccination 2)	2.3206 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	1.5100 titer

Secondary

Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4

Geometric Mean of RBD titer

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 29 Post Vaccination 1	1.4036 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	1.5587 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 85 Post Vaccination 1	1.5076 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	1.3002 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 57 Post Vaccination 1	1.0000 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	5.8158 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	1.7037 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	4.7615 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 1 Pre-Vaccination 1	1.3894 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	5.2214 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 1 Pre-Vaccination 1	1.8018 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 29 Post Vaccination 1	3.4419 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 57 Post Vaccination 1	3.3980 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 85 Post Vaccination 1	3.5077 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	4.3799 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	4.1463 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	3.9733 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	5.2318 titer

Secondary

Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A

Geometric Mean of S-2P titer

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 29 Post Vaccination 1	4.0618 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	3.5022 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	4.7630 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	5.6119 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 1 Pre-Vaccination 1	1.8212 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	4.6257 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 1 Pre-Vaccination 1	1.0000 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 29 Post Vaccination 1	1.9543 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	2.6772 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	1.6279 titer

Secondary

Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4

Geometric Mean of S-2P titer

Arm	Measure	Group	Value (GEOMETRIC_MEAN)
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 29 Post Vaccination 1	2.2027 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	2.0917 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 85 Post Vaccination 1	2.0479 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	2.6905 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 57 Post vaccination 1	2.3213 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	5.1576 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	2.3037 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	4.5632 titer
Stage 1 (Naïve) Group 1	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 1 Pre-Vaccination 1	1.2425 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	4.8462 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 1 Pre-Vaccination 1	1.3426 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 29 Post Vaccination 1	3.3798 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 57 Post vaccination 1	3.3500 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 85 Post Vaccination 1	3.2201 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	4.0985 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	3.9677 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	3.5196 titer
Stage 1 (Naïve) Group 3A	Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	4.7234 titer

Secondary

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A

Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 1 Pre-Vaccination	0.033 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 29 Post Vaccination 1	0.294 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	0.216 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 1 Pre-Vaccination	0.040 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 29 Post Vaccination 1	0.078 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	0.090 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.007 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.017 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.011 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.028 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.016 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.012 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.017 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.026 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.284 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.192 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.315 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.316 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.182 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.225 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.099 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.111 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.237 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.252 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.166 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.172 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.228 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.149 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.103 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.223 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A

Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 29 Post Vaccination 1	0.024 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	0.013 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 29 Post Vaccination 1	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.015 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.019 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.018 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.008 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.018 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.006 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.015 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.015 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.007 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.012 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.016 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.019 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.011 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.015 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.022 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.010 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.014 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.007 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.007 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.011 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.006 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.006 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.007 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.036 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.006 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.012 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.008 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.011 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.011 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.014 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.011 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.011 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.008 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.019 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.007 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.008 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.008 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.010 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.008 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.006 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.012 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.011 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0.001 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.006 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.009 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.007 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.006 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.005 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.005 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0.003 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0.004 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0.006 percentage of CD4+ T Cells

Secondary

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 1	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3A	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.001 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 3B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.020 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.002 percentage of CD4+ T Cells
Stage 1 (Naïve) Group 4	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.001 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.005 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.009 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.009 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.004 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	0.006 percentage of CD4+ T Cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0.003 percentage of CD4+ T Cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A

Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	18.125 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	42.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4

Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot

Time frame: Day 1 Pre-Vaccination 1, Day 29 Post Vaccination 1, Day 57 Post vaccination 1, Day 85 Post Vaccination 1, Day 99 Post Vaccination 1, Day 113 Post Vaccination 1, Day 169 Post Vaccination 1, Day 265 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	24.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the 15mer OLPa Spanning Nucleocapsid Frame as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	36.071 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	51.111 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	25.938 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	23.125 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	19.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	25.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	32.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	34.688 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	28.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	35.556 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	77.188 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	43.125 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	17.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	64.375 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	55.625 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	19.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	36.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	17.778 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	19.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	21.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	18.611 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	25.278 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	17.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	21.944 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	21.389 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	22.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	20.36 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	16.79 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	17.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	45.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	25.71 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	28.93 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	54.38 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	28.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	666.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	206.25 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A

Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	26.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	54.167 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	37.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	51.250 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4

Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 1 Pre-Vaccination 1	26.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 29 Post Vaccination 1	36.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 57 Post vaccination 1	40.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 85 Post Vaccination 1	18.750 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	21.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	31.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 29 Post Vaccination 1	24.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	24.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	23.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the 15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	72.143 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	68.611 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	39.063 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	57.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	62.222 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	33.056 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	37.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	72.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	49.444 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	48.611 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	97.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	53.750 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	22.500 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	90.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	89.688 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	25.250 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	63.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	17.778 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	22.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	37.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	37.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	33.611 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	24.722 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	32.778 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	27.778 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	31.07 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	38.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	18.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	58.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	25.71 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	38.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	51.88 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	34.38 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	31.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	812.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLP (Overlapping Peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	268.75 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A

Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	37.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	51.250 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4

Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 1 Pre-Vaccination 1	16.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 29 Post Vaccination 1	16.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	18.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the 15mer OLPs Spanning Membrane Frame as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	22.143 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	17.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	17.813 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	19.688 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	21.944 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	16.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	22.813 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	18.889 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	17.778 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	18.438 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	17.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	17.188 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	16.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	30.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	17.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	20.250 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	17.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	16.111 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	15.000 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	16.111 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	18.93 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Membrane Frame for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	15.00 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A

Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 29 Post Vaccination 1	16.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	29.375 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	21.667 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 29 Post Vaccination 1	18.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4

Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 1 Pre-Vaccination 1	28.333 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 29 Post Vaccination 1	37.917 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 57 Post vaccination 1	40.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 85 Post Vaccination 1	18.750 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	21.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	19.375 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	17.083 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 1 Pre-Vaccination 1	19.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 29 Post Vaccination 1	27.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	24.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	23.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the 15mer OLPs spanning Open Reading Frame 3a as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	42.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	30.278 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	26.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	44.063 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	46.667 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	18.889 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	22.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	34.688 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	31.944 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	28.611 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	31.250 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	23.750 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	20.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	37.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	42.188 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	21.250 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	24.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	19.250 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	22.000 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	28.056 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	22.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	20.556 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	24.167 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	19.722 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	29.29 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	17.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	26.07 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	19.64 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	18.33 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	27.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	17.14 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	26.79 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	18.13 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	20.63 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	22.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	31.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	157.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the 15mer OLPs Spanning Open Reading Frame 3a for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	70.00 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	61.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	76.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	120.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	257.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	17.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	230.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	29.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	37.500 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	29.167 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	34.167 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	25.833 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	31.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	22.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	33.125 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	28.333 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	33.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	328.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	24.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	28.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	43.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	35.833 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	193.214 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	201.389 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	118.438 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	153.438 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	160.278 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	130.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	157.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	195.938 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	151.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	148.000 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	137.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	112.500 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	109.688 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	170.313 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	163.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	146.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	210.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	56.389 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	117.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	117.750 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	117.222 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	137.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	117.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	105.278 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	95.833 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	140.71 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	73.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	132.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	118.21 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	82.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	431.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	197.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	437.86 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	415.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	412.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	45.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	40.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	208.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	1157.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 1st of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	827.50 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	131.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	140.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	250.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	525.833 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	90.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	25.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	28.750 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	21.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	16.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	30.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	304.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	83.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	72.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	17.500 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	151.429 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	143.611 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	101.563 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	146.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	143.056 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	143.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	158.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	486.875 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	183.889 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	188.250 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	116.563 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	125.313 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	118.438 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	155.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	150.625 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	115.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	166.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	61.389 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	104.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	101.750 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	131.667 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	124.167 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	124.167 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	116.667 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	79.167 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	139.64 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	95.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	127.14 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	108.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	122.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	93.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	58.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	87.86 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	81.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	83.13 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	25.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	576.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	1360.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 2nd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	1006.25 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	60.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	74.375 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	123.750 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	241.667 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	166.250 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	18.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	26.667 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	19.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	32.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	21.667 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	31.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	21.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	32.917 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	85.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	74.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	22.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	25.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	193.929 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	241.667 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	130.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	151.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	159.444 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	155.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	199.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	215.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	173.611 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	225.250 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	128.438 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	94.688 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	103.438 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	139.063 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	128.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	126.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	233.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	101.111 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	132.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	119.000 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	137.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	180.556 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	134.772 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	135.833 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	109.444 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	269.29 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	156.88 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	256.43 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	182.14 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	198.33 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	245.42 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	126.43 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	225.71 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	217.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	336.88 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	22.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	30.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	65.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	451.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 3rd of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	206.25 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	16.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	49.375 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	36.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	75.833 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	20.625 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	177.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 1 Pre-Vaccination 1	17.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 29 Post Vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	27.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	28.750 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	23.750 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	19.167 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	17.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	17.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	23.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	24.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 57 Post vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 3B and 4	Day 85 Post Vaccination 1	21.667 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	83.929 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	72.778 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	56.563 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	81.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	84.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	83.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	71.250 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	157.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	91.944 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	91.500 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	53.125 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	42.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	44.688 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	61.875 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	67.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	80.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	77.250 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	45.556 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	72.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	67.750 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	58.333 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	53.333 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	64.444 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	79.722 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	51.944 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	121.43 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	69.38 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	108.93 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	91.79 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	80.83 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	50.42 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	47.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	48.93 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	32.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	47.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	25.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	31.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	78.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Consensus Spike (Wuhan-1) Whole Protein, 4th of 4 OLP Pools for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	91.25 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A

Mean spot forming units per million of the S1 as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	216.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	370.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	775.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 29 Post Vaccination 1	189.375 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	312.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 29 Post Vaccination 1	29.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	55.000 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4

Mean spot forming units per million of the S1 as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 1 Pre-Vaccination 1	27.917 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 29 Post Vaccination 1	49.167 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 57 Post vaccination 1	22.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 85 Post Vaccination 1	26.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	25.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	33.125 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	44.583 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	324.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	404.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 29 Post Vaccination 1	20.833 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 1 Pre-Vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	90.833 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 57 Post vaccination 1	43.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 3B and 4	Day 85 Post Vaccination 1	35.833 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the S1 as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	344.643 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	345.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	218.125 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	300.313 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	303.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	268.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	313.250 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	674.375 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	348.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	334.000 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	249.375 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	230.313 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	224.375 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	322.500 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	306.875 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	254.250 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	371.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	110.833 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	213.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	212.750 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	237.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	247.778 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	243.722 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	209.444 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	160.556 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	276.43 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	165.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	259.64 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	223.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	196.67 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	520.83 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	246.79 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	516.43 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	486.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	488.13 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	45.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	40.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	773.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	2506.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	1833.75 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A

Mean spot forming units per million of the S2 as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	120.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	156.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	317.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 29 Post Vaccination 1	60.625 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	332.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 29 Post Vaccination 1	36.667 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	25.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	28.750 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4

Mean spot forming units per million of the S2 as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 29 Post Vaccination 1	41.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 85 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	31.250 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	21.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	35.417 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	90.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	74.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 29 Post Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	24.167 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 57 Post vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 3B and 4	Day 85 Post Vaccination 1	33.333 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the S2 as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	311.111 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	271.786 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	232.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	238.611 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	183.438 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	233.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	262.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	308.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	262.222 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	365.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	130.313 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	174.688 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	185.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	190.313 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	138.438 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	136.667 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	178.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	202.750 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	191.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	303.500 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	223.889 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	149.722 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	190.278 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	203.056 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	185.556 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	226.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	365.36 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	390.71 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	273.93 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	279.17 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	238.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	164.64 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	289.58 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	263.57 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	368.75 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	15.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	297.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	530.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	30.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the S2 for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	88.75 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A

Mean spot forming units per million of the Spike as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 29 Post Vaccination 1	250.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	336.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	527.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	1092.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	637.500 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 1 Pre-Vaccination 1	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 29 Post Vaccination 1	55.833 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	25.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	76.250 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4

Mean spot forming units per million of the Spike as measured by ELISpot

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 1 Pre-Vaccination 1	27.917 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 29 Post Vaccination 1	77.917 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 57 Post vaccination 1	22.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 85 Post Vaccination 1	26.875 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	45.625 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	40.000 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	67.500 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	406.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	473.333 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 1 Pre-Vaccination 1	20.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 29 Post Vaccination 1	20.833 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	105.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 57 Post vaccination 1	43.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 3B and 4	Day 85 Post Vaccination 1	59.167 SFU/million cells

Secondary

Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Mean spot forming units per million of the Spike as measured by ELISpot.

Time frame: Day 1 Pre-Vaccination 1, Day 15 Post Vaccination 1, Day 29 Post vaccination 1, Day 85 Post Vaccination 1, Day 181 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	541.944 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	616.429 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	401.563 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	532.813 SFU/million cells
Stage 1 (Naïve) Group 1	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	656.111 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	576.000 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	500.750 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	641.250 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	610.556 SFU/million cells
Stage 1 (Naïve) Group 3A	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	1038.438 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	510.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	360.938 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	360.625 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	492.813 SFU/million cells
Stage 1 (Naïve) Group 3B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	424.063 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	452.500 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	245.833 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	399.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	390.000 SFU/million cells
Stage 1 (Naïve) Group 4	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	670.000 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	423.333 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	405.833 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	418.056 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	305.278 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	466.667 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	625.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	667.14 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	391.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	497.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	475.83 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	849.38 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	807.92 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	407.14 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	717.50 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	775.71 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 1 Pre-Vaccination 1	855.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 85 Post Vaccination 1	70.00 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 15 Post Vaccination 1	2131.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 29 Post vaccination 1	3036.25 SFU/million cells
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Mean Spot Forming Units Per Million of the Spike for Groups 5, 6, 9, 10, 11, 13, 14, and 15	Day 181 Post Vaccination 1	45.00 SFU/million cells

Secondary

Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 1 arm consists of 3 participants as 1 participant did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	1.837 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.486 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.387 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	3.393 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	1.557 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	1.225 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.761 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	4.618 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.740 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	1.125 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.085 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	11.304 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	1.852 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	5.044 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	4.479 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	10.422 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	8.160 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	8.377 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	5.005 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	18.558 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	13.336 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	31.871 pg/mL

Secondary

Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay

Time frame: Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	6.466 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	1.538 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	1.072 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	9.715 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	3.250 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	3.565 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	1.208 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	13.257 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	2.050 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	3.042 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	0.808 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.271 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	0.161 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	0.156 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	0.070 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	2.167 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.391 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.064 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.341 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	2.534 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	1.361 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	3.895 pg/mL

Secondary

Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	22.599 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	11.987 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	26.108 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	37.991 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	15.392 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	42.650 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	329.048 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	80.641 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	30.663 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	367.540 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	12.384 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	1.724 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.569 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.499 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.657 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	1.934 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	1.158 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.144 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.522 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	3.091 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	1.666 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	4.757 pg/mL

Secondary

Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-10 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	6.628 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	1.021 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.778 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	8.160 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	1.533 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	2.561 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	1.124 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	10.722 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.541 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	2.269 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.438 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	6.348 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	1.264 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	2.151 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	2.972 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	21.391 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	5.901 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	5.602 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	3.856 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	27.292 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	9.458 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-10 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	36.750 pg/mL

Secondary

Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	3.361 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	3.736 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	2.124 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	7.645 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	6.043 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	3.324 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	2.597 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	9.936 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	2.342 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	7.390 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	5.252 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	7.095 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	4.728 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	2.279 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	2.156 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	2.156 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	5.175 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	6.298 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	6.298 pg/mL

Secondary

Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay

Time frame: Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	3.485 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	3.404 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	5.534 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	5.534 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	3.485 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	4.089 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	8.502 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.990 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	8.764 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	3.796 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	1.880 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	1.550 pg/mL

Secondary

Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	3.953 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	4.609 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	3.897 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	7.193 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	4.015 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	8.667 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	193.308 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	15.085 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	4.833 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	198.466 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	3.460 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	24.188 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	9.699 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	4.304 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	10.186 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	10.869 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	8.758 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	6.204 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	10.498 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	19.626 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	16.702 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	36.328 pg/mL

Secondary

Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-13 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	2.935 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	1.938 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	2.622 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	3.605 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	2.716 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	2.072 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	2.692 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	4.644 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	2.072 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	6.452 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	3.205 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	3.088 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	3.558 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	1.909 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	1.550 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	3.376 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	1.990 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	2.757 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	3.376 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	2.757 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-13 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	5.100 pg/mL

Secondary

Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	109.721 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	31.072 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	21.312 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	208.869 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	99.148 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	118.209 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	10.427 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	327.078 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	87.137 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	49.390 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	17.651 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	39.339 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	5.290 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	16.898 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	17.151 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	24.202 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	18.059 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	35.403 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	17.899 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	42.261 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	53.302 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	95.564 pg/mL

Secondary

Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay

Time frame: Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	24.703 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	32.809 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	15.310 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	49.324 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	24.621 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	58.201 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	5.648 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	107.524 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	25.392 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	34.713 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	13.754 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	42.267 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	18.749 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	11.485 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	12.042 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	31.098 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	20.411 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	24.891 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	31.035 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	51.509 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	55.926 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	107.435 pg/mL

Secondary

Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	41.112 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	16.322 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	32.492 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	48.035 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	6.923 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	34.309 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	956.979 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	82.343 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	17.987 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	994.717 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	5.246 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	31.671 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	11.715 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	10.155 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	9.801 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	25.725 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	12.611 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	21.148 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	16.493 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	38.335 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	37.641 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	75.976 pg/mL

Secondary

Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-2 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	129.978 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	51.847 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	26.168 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	214.659 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	87.681 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	143.474 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	16.116 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	358.132 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	91.627 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	57.817 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	15.533 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	50.703 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	15.847 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	19.297 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	15.559 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	732.268 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	755.178 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	727.250 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	689.798 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	1487.446 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	1417.047 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-2 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	2904.493 pg/mL

Secondary

Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.176 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	0.492 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.492 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	0.176 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.128 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	0.656 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.174 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.084 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.097 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.082 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.053 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.131 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.120 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	0.131 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	0.120 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	0.226 pg/mL

Secondary

Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay

Time frame: Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.047 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	0.038 pg/mL

Secondary

Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	0.082 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	36.585 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	0.082 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.082 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	36.585 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.493 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.299 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.063 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.186 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.126 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.601 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.075 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.260 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	0.708 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	0.315 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	1.024 pg/mL

Secondary

Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1

Mean T-cells Expressing IL-4 in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.059 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	0.097 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.076 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.109 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	0.097 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.098 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	0.047 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	0.052 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	0.038 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	0.056 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	0.052 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	0.056 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing IL-4 in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	0.071 pg/mL

Secondary

Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1

Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	17.145 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	7.229 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	6.100 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	35.990 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	18.845 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	16.941 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	6.784 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	52.931 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	9.712 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	21.729 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	8.845 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	58.926 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	12.990 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	27.390 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	18.547 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	72.302 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	35.237 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	44.250 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	27.882 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S1	107.539 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	S2	72.131 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 1 and 3A at Day 29 Post Vaccination 1	Spike	179.671 pg/mL

Secondary

Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay

Time frame: Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 3 participants as 4 participants did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	18.952 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	7.486 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	6.162 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	27.501 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	8.549 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	16.770 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	7.971 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	44.271 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	9.284 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	19.533 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	5.400 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	10.056 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs Spanning Membrane Frame	3.213 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPa Spanning Nucleocapsid Frame	4.853 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	15mer OLPs spanning Open Reading Frame 3a	1.989 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	13.546 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	5.384 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	7.804 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	5.214 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S1	18.930 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	S2	13.018 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	Spike	31.948 pg/mL

Secondary

Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1

Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 3B arm consists of 2 participants as 5 participants did not have any data reported for this outcome. The Group 4 arm consists of 2 participants as 1 participant did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	167.163 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	123.765 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	300.416 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	312.503 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	145.340 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	414.445 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	1861.230 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	726.948 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	290.681 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	2290.337 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	128.731 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	10.371 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	3.194 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	3.744 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	3.433 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	10.697 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	5.505 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	6.443 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	6.927 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S1	16.202 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	S2	13.370 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 3B and 4 at Day 29 Post Vaccination 1	Spike	29.572 pg/mL

Secondary

Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1

Mean T-cells Expressing TNF-alpha in pg/mL as measured by MSD cytokine assay

Time frame: Day 29 Post Vaccination 1

Population: The mITT population includes all enrolled participants who received at least one dose vaccine and contributed both pre- and at least one post vaccination venous blood sample for the corresponding immunogenicity endpoint testing and for which valid results were reported. The Group 5 and 6 arms consist of 3 participants as 7 participants in each arm did not have any data reported for this outcome.

Arm	Measure	Group	Value (MEAN)
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	14.317 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	10.754 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	10.909 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	42.900 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	30.201 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	25.071 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	7.161 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	67.971 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	12.700 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	25.493 pg/mL
Stage 1 (Naïve) Group 1	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	7.423 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLP (overlapping peptides) Spanning Membrane, Nucleocapsid, and Open Reading Frame 3a	48.272 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs Spanning Membrane Frame	11.752 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPa Spanning Nucleocapsid Frame	20.224 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	15mer OLPs spanning Open Reading Frame 3a	16.296 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 1st of 4 OLP pools	209.438 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 2nd of 4 OLP pools	96.215 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 4th of 4 OLP pools	71.193 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S1	305.653 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	S2	140.002 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Spike	445.655 pg/mL
Stage 1 (Naïve) Group 3A	Mean T-cells Expressing TNF-alpha in pg/mL for Groups 5 and 6 at Day 29 Post Vaccination 1	Consensus Spike (Wuhan-1) whole protein, 3rd of 4 OLP pools	68.809 pg/mL

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.1 S-2P

Time frame: Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	75 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	50 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 29 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 85 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	33 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	33 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 29 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 57 Post vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 85 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	33 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	0 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.1 S-2P

Time frame: Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	86 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.1 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against BA.4/5 S-2P

Time frame: Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	75 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P

Time frame: Day 169 Post Vaccination 1 (85 Days Post Vaccination 2), Day 265 Post Vaccination 1 (181 Days Post Vaccination 2), Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	60 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against BA.4/5 S-2P

Time frame: Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	90 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	86 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	86 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against BA.4/5 S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P

Time frame: Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2), Day 209 Post Vaccination 1 (181 Days Post Vaccination 2), Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 29 Post Vaccination 1	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 394 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 29 Post Vaccination 1	67 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 209 Post Vaccination 1 (181 Days Post Vaccination 2)	50 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	33 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution) against D614G S-2P

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 29 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 57 Post vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 85 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	17 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	17 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	0 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 450 Post Vaccination 1 (366 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 29 Post Vaccination 1	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 113 Post Vaccination 1 (29 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 57 Post vaccination 1	67 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 265 Post Vaccination 1 (181 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 85 Post Vaccination 1	0 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 169 Post Vaccination 1 (85 Days Post Vaccination 2)	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 3B and 4	Day 99 Post Vaccination 1 (15 Days Post Vaccination 2)	100 percentage of participants

Secondary

Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Percent of Participants Who Seroconverted, defined as a 4-fold change in Pseudovirus Neutralization ID50 (50% Inhibitory Dilution), against D614G S-2P

Time frame: Day 15 Post Vaccination, Day 29 Post Vaccination, Day 85 Post Vaccination, Day 181 Post Vaccination, Day 366 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 1	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3A	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 3B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 1 (Naïve) Group 4	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 366 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 181 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 85 Post Vaccination	100 percentage of participants
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Participants Who Seroconverted Based on Pseudovirus Neutralization ID50 Against D614G S-2P for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 29 Post Vaccination	100 percentage of participants

Secondary

Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A

Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 1 Pre-Vaccination	25 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 29 Post Vaccination 1	75 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	75 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 1 Pre-Vaccination	50 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 29 Post Vaccination 1	50 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	50 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	89 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	70 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	80 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	80 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	63 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	100 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	38 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	56 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	80 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	70 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	67 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	67 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	57 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	86 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	50 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	50 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A

Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154 To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 57 Post vaccination 1 (29 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	25 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A	Day 57 Post vaccination 1 (29 Days Post Vaccination 2)	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with Any COV2 S stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	1 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	10 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	13 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	20 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	10 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	11 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	13 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	20 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	14 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with Any TCE stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	13 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	10 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	11 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with G-Mem stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	13 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	20 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	14 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with G-Nuc stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	13 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IFNg and/or IL-2. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-values using the Bonferroni-Holm adjustment method. If the adjusted p-value for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Percent of Responders: CD4+ T Cells with G-ORFa stimulation expressing IL-4 or IL-5 or IL-13 and CD154. To assess positivity for a peptide pool within a T cell subset, a two-by-two contingency table was constructed comparing the stimulated and negative control data. The four entries in each table were the number of cells positive for the cytokine of interest and the number of cells negative for the cytokine, for both the stimulated and the negative control data. A one-sided Fisher's exact test was applied to the table, testing whether the number of cytokine-producing cells for the stimulated data was equal to that for the negative control data. Since multiple individual tests (for each peptide pool) were conducted simultaneously, a multiplicity adjustment was made to the individual peptide pool p-vals using the Bonferroni-Holm adjustment method. If the adjusted p-val for a peptide pool was =0.00001, the response to the peptide pool for the T cell subset was considered positive.

Time frame: Day 1 Pre-Vaccination, Day 29 Post Vaccination 1, Day 85 Post Vaccination 1, Day 99 Post vaccination 1 (15 Days Post Vaccination 2)

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 99 Post vaccination 1 (15 Days Post Vaccination 2)	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 29 Post Vaccination 1	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4	Day 85 Post Vaccination 1	0 percent of responders

Secondary

Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Time frame: Day 1 Pre-Vaccination, Day 15 Post Vaccination

Arm	Measure	Group	Value (NUMBER)
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 1	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3A	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	13 percent of responders
Stage 1 (Naïve) Group 3B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 1 (Naïve) Group 4	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 5	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After EUA/Licensed mRNA COVID-19 Vaccines) Group 6	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 9	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 1 Pre-Vaccination	0 percent of responders
Stage 2 (SAM-S-TCE Boosts After Approved/Licensed mRNA COVID-19 Vaccines) Group 10A,B	Percent of Responders: CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15	Day 15 Post-Vaccination	0 percent of responders

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Frequency of Any Laboratory AE

Frequency of Any Medically Attended Adverse Events (MAAEs)

Frequency of Any New-onset Chronic Medical Conditions (NOCMCs)

Frequency of Any Potentially Immune-mediated Medical Conditions (PIMMCs)

Frequency of Any Serious Adverse Events (SAEs)

Frequency of Any Unsolicited Adverse Events (AEs)

Frequency of Local Solicited Reactogenicity Adverse Events (AEs)

Frequency of Systemic Solicited Reactogenicity Adverse Events (AEs)

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4

Geometric Mean Fold Rise of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean in Titer of RBD IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean in Titer of S-2P IgG as Measured by ELISA for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 1 and 3A

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 3B and 4

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.1 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 1 and 3A

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 3B and 4

Geometric Mean of Pseudovirus Neutralization ID50 Against BA.4/5 for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 1 and 3A

Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 3B and 4

Geometric Mean of Pseudovirus Neutralization ID50 Against D614G for Groups 5, 6, 9, 10, 11, 13, 14, and 15

Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 1 and 3A

Geometric Mean Titer of RBD IgG as Measured by ELISA for Groups 3B and 4

Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 1 and 3A

Geometric Mean Titer of S-2P IgG as Measured by ELISA for Groups 3B and 4

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 1 and 3A

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 1 and 3A

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells With Any COV2 S Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells With Any TCE Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells With G-Mem Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells With G-Nuc Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 3B and 4

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IFNg and/or IL-2 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 3B and 4

Mean Percent of CD4+ T Cells With G-ORFa Stimulation Expressing IL-4 or IL-5 or IL-13 and CD154 for Groups 5, 6, 9, 10, 11, 13, 14 and 15

Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 1 and 3A

Mean Spot Forming Units Per Million of the 15mer OLPa Spanning Nucleocapsid Frame for Groups 3B and 4